NCT06789562

Brief Summary

Is to compare F-18 FDG PET/CT to routine CT in staging of non-small lung cancer and effect on change management.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P25-P50 for all trials

Timeline
19mo left

Started Jan 2025

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress47%
Jan 2025Dec 2027

First Submitted

Initial submission to the registry

January 18, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 23, 2025

Completed
7 days until next milestone

Study Start

First participant enrolled

January 30, 2025

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

January 23, 2025

Status Verified

January 1, 2025

Enrollment Period

2.8 years

First QC Date

January 18, 2025

Last Update Submit

January 22, 2025

Conditions

Lung Cancer

Outcome Measures

Primary Outcomes (1)

  • compare F-18 FDG PET/CT to routine CT in staging of non-small lung cancer and effect on change management.

    detect added value of F-18FDG PET/CT .

    Baseline

Interventions

F-18FDG PET/CT and CTDEVICE

compare F-18 FDG PET/CT to routine CT in staging of non-small lung cancer and effect on change management.

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

adult patients with non small lung cancer underwent initial F-18FDG PET/CT

You may qualify if:

  • Patients with pathologically proven NSCLC who underwent initial PET/CT images.
  • All patients ≥ 18 years.

You may not qualify if:

  • Patients who had started treatment before initial PET/CT. Patients with glucose level \< 200 mg/dl. Patients with another malignant condition.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Hadar R, Slonim A, Kuhn J. Role of D-tryptophan oxidase in D-tryptophan utilization by Escherichia coli. J Bacteriol. 1976 Mar;125(3):1096-1104. doi: 10.1128/jb.125.3.1096-1104.1976.

    PMID: 3493BACKGROUND

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Central Study Contacts

Walaa Gamal, assistant lecturer

CONTACT

01065037395dr.walaa196@gmail.com

Nahla Moustafa, assistant professor

CONTACT

01009466255Nahla_bashank_2006@yahoo.com

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant leacturer

Study Record Dates

First Submitted

January 18, 2025

First Posted

January 23, 2025

Study Start

January 30, 2025

Primary Completion (Estimated)

November 30, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

January 23, 2025

Record last verified: 2025-01